Supernus Pharmaceuticals Announces Conference Call for Q3 2024
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) has just revealed exciting news regarding its upcoming conference call, set to take place soon. This biopharmaceutical company specializes in creating innovative treatments for central nervous system (CNS) diseases and is expected to share significant updates pertaining to its financial performance during the third quarter of 2024.
Date and Timing of the Conference Call
The conference call is scheduled for November 4, 2024, at 4:30 p.m. ET. Jack Khattar, President and CEO, alongside Timothy Dec, Senior Vice President and CFO, will lead the discussion. They will present the latest financial data as well as insights into the company’s business strategy and results for the quarter.
Joining the Conference Call
Participants who wish to join this important event can register in advance. This ensures that attendees receive a dial-in number and a personalized entry code. To make the most out of this event, it's suggested that participants call in around 15 minutes before the discussion begins to ensure they are connected in time.
Webcast Access
The live webcast will be made available on the Investor Relations page of Supernus Pharmaceuticals' website, giving stakeholders access to the discussions and updates in real time. For anyone who cannot attend the live session, a recording will be accessible for a period of 60 days following the event, allowing additional opportunities to catch up on crucial information.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is dedicated to developing and marketing products that cater to patients suffering from CNS diseases. With a solid commitment to innovation, the company has developed a range of therapies aimed at treating epilepsy, migraine, and attention deficit hyperactivity disorder (ADHD) among others.
Products in Development
The company's portfolio continues to expand, as it explores potential new treatment options aimed at addressing conditions such as hypomobility in Parkinson's disease (PD), depression, and other CNS disorders. This ongoing research and development narrative reflects Supernus Pharmaceuticals’ proactive approach to enhancing the quality of life for patients affected by these challenging conditions.
Commitment to Investor Engagement
Supernus Pharmaceuticals consistently prioritizes its investor community by keeping them informed and engaged. Their dedication is reflected in regular updates through conference calls, webcasts, and other informative sessions that share insights about the company’s performance and future direction.
Contact Information
If you have any questions or require further information, you can reach the executive team directly. Jack A. Khattar, the President and CEO, alongside Timothy C. Dec, Senior Vice President and CFO, are available for any inquiries. They can be reached at Supernus Pharmaceuticals, Inc. at (301) 838-2591.
Additionally, the investor relations department is led by Peter Vozzo from ICR Westwicke. He can be contacted for focused investor-related inquiries at (443) 213-0505 or via mobile at (443) 377-4767. For direct communication, interested parties can email him at peter.vozzo@westwicke.com.
Frequently Asked Questions
What is the purpose of the Supernus Pharmaceuticals conference call?
The conference call aims to discuss the financial results and business strategies for the third quarter of 2024.
When will the conference call take place?
The call is scheduled for November 4, 2024, at 4:30 p.m. ET.
How can I participate in the conference call?
You can pre-register for the call to receive your dial-in information and personalized code.
Will a recording of the call be available later?
Yes, a replay will be accessible on the Company’s Investor Relations website for 60 days following the live event.
Who can I contact for more information?
You can contact Jack A. Khattar or Timothy C. Dec at Supernus Pharmaceuticals, or reach out to Peter Vozzo from ICR Westwicke for investor relations inquiries.
